Browse Articles

Discover research articles across all indexed journals

Cardiovascular mortality risk in primary penile cancer patients: A retrospective cohort study from 2000 to 2021.

Journal of Clinical Oncology Asfand Yar Cheema, Mishaal Munir, Aashray Mandala et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.7

7 Background: Primary penile cancer is a rare malignancy, representing less than 1% of all cancers in men in developed countries. The disease predominantly affects older males and is frequently associated with risk factors such as human papillomavirus (HPV) infection, chronic inflammation, smoking, and poor hygiene. Given the age and comorbidities of patients diagnosed with penile cancer, cardiovascular disease (CVD) is a significant concern. Penile cancer patients often present with multiple risk factors for CVD, including advanced age, smoking, obesity, and pre-existing hypertension. Despite improvements in cancer-specific survival, non-cancer causes of death, particularly cardiovascular mortality (CVM), may disproportionately affect these patients. Understanding the cardiovascular mortality in penile cancer patients is crucial for holistic care and survivorship. Methods: We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with primary penile cancer who experienced cardiovascular mortality (CVM) between 2000 and 2021. CVM was defined as mortality resulting from heart disease, hypertension (without concomitant heart disease), cerebrovascular disease, atherosclerosis, aortic aneurysm and dissection, and other diseases of the arteries, arterioles, and capillaries. Standardized mortality rates (SMR) were calculated to assess the relative risk of CVM among penile cancer patients compared to the general population. Absolute excess risk (AER) was also estimated to quantify the additional number of CVM-related deaths attributed to this patient population. Results: Out of a total cohort of 6,889 patients diagnosed with primary penile cancer, 689 experienced cardiovascular mortality. Patients with Non-cardiovascular death and patients with unknown ag, race and cancer stage were excluded. We compared the CVM of each group to the general US population. In our cohort based on race we didn't note statistically significant increase in CVD SMRs. Regarding race American Indians/Alaska Natives has (SMR 0.99, CI 0.24-3.98), Asians or Pacific Islanders (SMR 0.99 CI 0.68-1.46), Blacks (SMR 0.99 CI 0.75-1.33), Whites (SMR 1.00 CI 0.91-1.08). In terms of age, patients aged 30-50 years (n=27) had SMR of 0.99 (CI 0.68-1.44), 50-79 year (n=359) had SMR of 0.99 (CI 0.90-1.10), while 80 years and above (n=222) had SMR of 1.00 (CI 0.87-1.14). Conclusions: Our analysis evaluates the burden of CVD-related mortality in patients with primary penile carcinoma. In this cohort, no statistically significant increase in cardiovascular mortality was observed when compared to the general U.S. population, stratified by race and age. Further research is required to better understand potential associations or disparities and to identify any underlying factors that may influence cardiovascular outcomes in this population.

Network analysis of the relationship between error orientation, self-efficacy, and innovative behavior in nurses

Scientific Reports Guiyue Ma, Xiaoqin Ma Feb 10, 2025 DOI: 10.1038/s41598-025-87736-8

Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.

Journal of Clinical Oncology Gabriela Gazzoni, Maysa Vilbert, João Pedro Oliveira et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.761

761 Background: Enfortumab vedotin (EV) is an antibody-drug conjugate that binds nectin-4, a cell-adhesion molecule highly expressed in urothelial carcinoma (UC) and epidermal keratinocytes. Dermatologic events have become important EV-related toxicities in clinical trials (CT) and observational studies. We conducted a systematic review and meta-analysis on skin toxicity in UC patients treated with EV. Methods: We systematically searched Pubmed, Cochrane, and Embase for published CT and observational studies reporting EV-related skin toxicities in UC patients. We investigated treatment-related adverse events (TRAE) and severe cutaneous adverse reactions (SCAR) in UC patients of all-grade and ≥ 3. The outcomes were presented as overall incidence rates and 95% confidence intervals (95% CI). Statistical analyses were performed using R software. Results: Ten studies comprising 1,061 participants were included. Median age ranged from 66 to 76 years, and 74% (783) were male. 72% of patients had prior immune checkpoint inhibitors. The median time to onset of skin toxicity varied from two to four weeks. In a pooled analysis, the skin reaction rate for all-grade of UC was 50% (95% CI 38-61), while for grade ≥ 3 was 10% (95% CI 7-15). The incidence of SCAR was 19% (95% CI 16-23) and 8% (95% CI 3-18) for grade ≥ 3. Alopecia was seen in 37% of patients, pruritus in 22% and dry skin in 21%. All-grade rash incidence rate was 29% and the most reported was maculopapular rash 22%, followed by erythematous rash (6%). Important cutaneous reactions included bullous dermatitis in 2.91% of patients (95% CI 1-6), palmar-plantar erythrodysesthesia in 2.46% (95% CI 1-5), Stevens-Johnson syndrome in 1.46% (95% CI 0.4-5), and toxic epidermal necrolysis in 0.95% (95% CI 0.2-4) of patients. Conclusions: This is the first study to characterize EV-related dermatological toxicities. We found a high incidence of all-grade events and a moderate frequency of severe and grade ≥ 3 toxicities. This study intends to highlight the need for close monitoring and adequate treatment for skin toxicities in UC patients receiving EV.

Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial.

Journal of Clinical Oncology Robert J. Thomas, Stacey A Kenfield, Paul U Newton et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.311

311 Background: The "gut-prostate axis" is increasingly being recognised as an influencer of prostate cancer (PCa) incidence and progression via its affect on inflammation, oxidative stress and immune surveillance. Murine models have shown that improving the gut microbiome can slow cancer progression. Boosting phytochemical rich foods (PRF) has previously been shown to inhibit Prostatic Specific Antigen (PSA) progression in men with indolent PCa and are potent prebiotics, working in synergy with lactobacillus probiotics, and vitamin D. Until now, no study has evaluated this dietary combination in men with PCa. Methods: 212 men with PSA progressing PCa (average age 74.5 years) managed with surveillance were given a Phytochemical Rich Supplement (PRS), uniquely containing both standardised extracts and whole purified organic ginger, cranberry, pomegranate, turmeric, broccoli and green tea. Men were then randomised (1:1) to a placebo (P) or a Probiotic blend (PB) of 5 lactobacillus probiotics with prebiotic inulin and vitamin D, for 16 weeks. Results: For the 105 men on PRS+P, the average rate of PSA rise pre to post baseline changed from 19.6% to 6.2% - a statistically significant (SS) reduction of 13.4% (a paired t-test p<0.01). For the 107 men on PRS/PB, the rate changed from a 21.7% rise to a 20% fall - a reduction of 41.7% (p<0.0001). There was a SS greater difference in PSA dynamics comparing the PRS+BP v PRS+P groups (28.3%, p<0.0001).The International Prostate Symptom Score and the International Index of Erectile Function were SS better in the PRS+PB v PRS+P men (10.5 v 14.1; 26.6 v 23.7 respectively, both P<0.001). Both arms had good tolerance, 5% had some bloating but conversely 14% reported improved gut symptoms. There was no difference in testosterone levels. Pre and post MRI was available in 180 men to date. In 10, the disease was reported to shrink, 164 stabilised and 6 worsen with PSA progression at a higher than average rate in all these 6, suggesting no PSA masking effect. Conclusions: This new phytochemical rich food supplement significantly slowed PSA progression, improved urinary symptoms and erectile function in men with indolent PCa. In addition, this is the World's first double blind RCT to demonstrate that an intervention aiming to improve gut health using pre and probiotics further reduced PSA progression. Hopefully, these findings will encourage more microbiome related research in men with PCa. Further follow up will determine whether this slowing of PSA progression influenced men's decision to avoid the toxicities of radical interventions. MRI images, so far, are reassuring but longer follow up is also planned. This evidence based information, will help dietary choices and will be welcomed by men on surveillance, with whom this trial was designed. Clinical trial information: 81939514.

Prognostic value of preoperative fibrinogen in metastatic clear cell renal cell carcinoma patients undergoing cytoreductive nephrectomy: A propensity score-matched study.

Journal of Clinical Oncology Jianzhong Shou, Honglei Cui, Xingang Bi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.563

563 Background: The measurement of serum fibrinogen (FIB) levels is often overlooked in metastatic clear cell renal cell carcinoma (mccRCC). This study aims to investigate the prognostic value of preoperative serum FIB levels in mccRCC patients undergoing cytoreductive nephrectomy (CN) followed by systemic therapy. Methods: This retrospective study analyzed 209 mccRCC patients who underwent CN from 2010 to 2022. The optimal cutoff value of preoperative serum FIB levels was determined via receiver operating characteristic (ROC) curve. Survival outcomes were evaluated by the Kaplan-Meier method and Cox proportional hazards models. The predictive ability was evaluated by ROC curve. Propensity Score Matching (PSM) was performed to equate demographic and clinical characteristics. Results: An optimal cutoff value of 4.39 g/L for the FIB levels was determined and patients were categorized into high and low FIB groups. With a median follow-up time of 61.1 months, patients in the low FIB group exhibited significantly higher median OS compared with the high FIB group (53.1 vs 27.9 months, p < 0.001). The ROC curve demonstrated that the serum FIB predicted a 36-month overall survival with an AUC of 0.652, while the AUC for the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk category was 0.558. After PSM matching, high FIB levels remained significantly associated with poorer OS (24.0 vs 50.2 months; p = 0.019). Conclusions: Serum FIB level is a significant prognostic factor for mccRCC patients undergoing CN followed by systemic therapy. This finding underscores the potential of FIB as a biomarker that could be integrated into the prognostic model for preoperative risk stratification and management strategies.

A data augmentation model integrating supervised and unsupervised learning for recommendation

Scientific Reports Jiaying Chen, Zhongrui Zhu, Haoyang Li et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88858-9

Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.

Journal of Clinical Oncology Xinan Sheng, Cuijian Zhang, Yongpeng Ji et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.665

665 Background: This single-arm phase II trial was conducted to evaluate the efficacy and safety of neoadjuvent disitamab vedotin (DV, a HER2-targetted monoclonal antibody conjugated with monomethyl auristatin E) plus perioperative toripalimab (an anti-PD-1 inhibitor) in MIBC patients (pts) with HER2 expression. The preliminary results showed promising efficacy and acceptable safety with neoadjuvant treatment with DV plus toripalimab in pts with HER2-expressing MIBC (Sheng, et al. ASCO Annual meeting 2024). Methods: Key eligibility criteria included previously untreated MIBC (cT2-4aN0-1M0) with HER2 expression (immunohistochemistry [IHC] ≥1+ by local test), and eligible for curative-intent radical cystectomy and pelvic lymph node dissection (RC+PLND). Pts received DV (2 mg/kg) plus toripalimab (3 mg/kg) every 2 weeks for 6 cycles at neoadjuvant phase. After RC+PLND, pts received adjuvant toripalimab (3 mg/kg every 2 weeks) for up to 20 cycles. The primary endpoint was pathological complete response (pCR, ypT0N0) rate assessed by the investigators; secondary endpoints included pathological response rate (≤ypT1N0M0), overall survival, safety, etc. Here we present the updated efficacy and safety results and post-hoc event-free survival (EFS) analysis with data cutoff date (DCO) of September, 2024. Results: As of DCO, patient enrollment was completed with 47 pts enrolled and treated (including 10.6% pts with HER2 IHC 1+, 57.4% IHC 2+, and 31.9% IHC 3+; 83.0% pts at baseline T2-4N0M0 and 17.0% at cT2-4aN1M0 stage). RC+PLND was performed in 33 (70.2%) pts. The pCR rate was 63.6% (95% CI: 45.1%-79.6%) and the pathological response rate was 75.8% (95% CI: 57.7%-88.9%). A higher pCR rate of 84.6% was observed in patients with HER2 IHC 3+. The pCR rate was 77.8% and 62.5% in PD-L1-positive and PD-L1-negative subgroups, respectively. The one-year EFS rate was 89.5% (95% CI: 69.8%-96.7%). The safety profile was consistent with the previous ASCO presentation without new toxicity signals observed. No adverse events delayed the surgery. Survival data were immature. Conclusions: The updated data supported perioperative treatment with DV plus toripalimab had promising efficacy and acceptable safety in pts with HER2-expressing MIBC. It warrants further investigation in this patient population. Clinical trial information: NCT05297552 .

Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).

Journal of Clinical Oncology John Arthur Taylor, Shreyas Joshi, Raj Satkunasivam et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.802

802 Background: Detalimogene voraplasmid is a novel, investigational, non-integrating, non-viral gene therapy specifically engineered for intravesical administration to elicit local activation of anti-tumor immune responses in the bladder and drive durable efficacy in patients with high-risk NMIBC, including BCG-unresponsive disease, while mitigating the risk of systemic toxicities from immune stimulation. Preclinically, detalimogene voraplasmid remodels the tumor microenvironment, activating both innate and adaptive anti-tumor immune responses. Results from the Phase 1 portion of LEGEND (NCT04752722) demonstrated a promising safety/tolerability profile and an overall CR of 73% in patients with NMIBC with CIS. The pivotal Phase 2 portion is ongoing, and the preliminary outcomes will be reported herein. Methods: Patient eligibility criteria: age ≥18 years; ECOG PS 0−2; BCG-unresponsive NMIBC with CIS ± Ta/T1 disease, ineligible for, or elected not to undergo, cystectomy; satisfactory bladder function with ability to retain study drug for ≥60 minutes. Based on the Phase 1 portion of the study, a dose concentration of 0.8 mg/mL was administered at a four-dose 50 mL instillation schedule at study weeks 1, 2, 5 and 6 of a 12-week cycle. After completing the initial 12-week cycle, patients without progressive disease remained on detalimogene voraplasmid for up to three additional 12-week cycles. Primary endpoint: Week 48 CR rate; secondary endpoint: safety and tolerability. Efficacy data on BCG-unresponsive patients with CIS (n=26; Cohort 1) and safety data on all patients dosed (N=42) are reported. Results: Twenty-six patients (20 males/6 females; median age 74 (range 47–92) years have been enrolled in Cohort 1. Treatment-related adverse events (TRAEs; any grade) were reported in 20 (47.6%) patients and were all Grade 1/2 in severity. The most common TRAEs were dysuria in 9 (21.4%) patients, bladder spasm in 8 (19.0%); pollakiuria in 5 (11.9%), and fatigue in 5 (11.9%) patients. In the efficacy-evaluable population for Cohort 1, the overall CR rate was 71% (15/21), with a CR rate of 67% (14/21) at 3 months, and 47% (8/17) at 6 months. The Kaplan-Meier estimate of the 6-month CR is 51%. Conclusions: Preliminary data from the pivotal Phase 2 portion of the LEGEND study suggest a promising safety/tolerability profile, with TRAEs that were largely consistent with instrumentation/intravesical administration. Overall, 71% of patients dosed with detalimogene voraplasmid achieved a CR, with 67% achieving a CR at 3 months and 47% achieving a CR at 6 months. Cohort 1 (BCG-refractory patients with CIS) continues to enroll, with a target accrual of 100 patients. Clinical trial information: NCT04752722 .

Clinical characterization and treatment patterns in patients with metastatic hormone-sensitive prostate cancer at three third-level centers of the Mexican Institute of Social Security: A retrospective cohort study.

Journal of Clinical Oncology Samuel Rivera, Libny Martinez-Valdez, Miguel Enrique Cuellar Mendoza et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.91

91 Background: In Latin America, prostate cancer (PC) is the most common cancer among men. Despite efforts in select institutions in Mexico to register and organize data on patients (pts) with PC, epidemiological data are scarce. This study described the demographic, clinical, and treatment-related characteristics of pts with metastatic hormone-sensitive PC (mHSPC) in reference centers for the Mexican Institute of Social Security (IMSS). Methods: This retrospective, observational, cohort study examined the health records of adult (≥18 years) pts newly diagnosed with mHSPC between January 1, 2017, and June 30, 2023. The pts were treated at one of the three tertiary hospitals of the IMSS and received ≥1 follow-up consultation after the date of mHSPC diagnosis. Criteria for mHSPC diagnosis: ICD-10 code C61 or D40; inclusion of “prostate cancer,” “adenocarcinoma of the prostate,” or “malignant tumor of the prostate” in pt charts; radiologic confirmation and stage IV/metastatic disease diagnosis by an oncologist/urologist; hormone sensitivity with/without prior androgen-deprivation therapy (ADT) (having stopped ADT ≥12 months before confirmation of metastatic disease); or clinically equivalent diagnosis. Pts were stratified by the tumor, node, metastasis (TNM) staging system of PC (8 th ed). Only metastatic disease (i.e., any T or N and M1) was considered at baseline. Results: In total, 454 pts’ charts were reviewed:246 did not have metastatic disease, 42 had metastatic castration-resistant prostate cancer, and 166 (37%) had mHSPC. Of these 166 pts (median [SD] age, 69.5 [8.3] years),71% (n = 117)had Gleason score ≥8, 20% (n = 33) had confirmed nodal spread (N1), and 65% (n = 108) had confirmed metastasis (M1) at the time of diagnosis. Pts received the following treatments (n, %): gonadotropin-releasing hormone (GnRH) agonist (144, 87%), GnRH antagonist (5, 3%), orchiectomy (3, 2%), androgen receptor pathway inhibitor (32, 19%), and chemotherapy (31, 19%). In 35 pts, ADT was discontinued due to biochemical progression (20%), radiological progression (6%), radiological and biochemical progression (3%), or progression due to an unspecified cause (9%). There were 10 adverse events (AEs): 4 pts had grade 3 AEs, 5 pts had grade 4 AEs, and 1 pt had an AE of unspecified grade. Conclusions: This study identified clinical characteristics of and treatment variations in pts with mHSPC at the IMSS. Treatment patterns differed despite consensus in clinical guidelines. These results may help drive critical analyses of clinical decision-making, inform optimal data collection practices, and support the strengthening of cancer registries in Mexico.

A prediction model of soil organic carbon into river and its driving mechanism in red soil region

Scientific Reports Yanhu He, Yuyin Yang, Daoguo Xu et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88386-6

Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology William Kevin Kelly, Sandy Srinivas, Joseph Maly et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps295

TPS295 Background: mCRPC is characterized by an immunosuppressive tumor microenvironment with few intratumoral effector T cells, leading to low response rates to immune checkpoint inhibitors; therefore, novel immunotherapy approaches are needed. Prostate-specific membrane antigen (PSMA) is highly expressed in malignant prostate cancer cells. REGN4336 is a PSMA×CD3 bispecific antibody (bsAb) that facilitates T-cell–mediated tumor killing by bridging PSMA-expressing tumor cells with CD3+T cells, providing “signal 1” for T-cell activation. Nezastomig (REGN5678 [PSMA×CD28 bsAb]) enhances T-cell activation/proliferation by engaging the costimulatory receptor CD28 on T-cells located in proximity to PSMA, providing “signal 2.” In preclinical models, REGN4336 demonstrated dose-dependent activity against PSMA-expressing tumor cells that was enhanced in combination with cemiplimab (anti–PD-1) or nezastomig. Preclinically, nezastomig + subtherapeutic doses of REGN4336 showed similar efficacy and reduced cytokines compared with higher doses of REGN4336 monotherapy, suggesting this strategy may mitigate cytokine release syndrome (CRS). In a separate clinical trial (NCT03972657), nezastomig + cemiplimab demonstrated promising clinical activity in mCRPC, but some responders had high-grade immune-mediated AEs. REGN4336 is a novel combination partner for nezastomig. Methods: This is an open-label, Phase 1/2, first-in-human, multicenter study evaluating REGN4336 ± cemiplimab or nezastomig in pts with mCRPC (NCT05125016). Pts must have received ≥2 lines of systemic therapy for metastatic/castration-resistant disease, including a second-generation anti-androgen. Prior PSMA-targeted radioligands are permitted. Module 1 evaluates REGN4336 monotherapy with step-up dosing to mitigate CRS; Module 2 will evaluate REGN4336 + cemiplimab; Module 3 evaluates REGN4336 + nezastomig. In Modules 2 and 3, pts will receive REGN4336 step-up dosing until tolerated with Grade ≤1 CRS, followed by combination therapy. Module 1 began with REGN4336 administered SC; in addition, Modules 1–3 may evaluate REGN4336 administered IV (+ sarilumab [anti–IL-6] for CRS prophylaxis) to compare tolerability, PK, and immunogenicity across routes. Treatment continues until disease progression, intolerable AEs, or other withdrawal criteria are met. Dose escalation primary objectives: assess safety, tolerability, and PK, and determine RP2D regimens of REGN4336 ± cemiplimab or nezastomig. Dose expansion primary objectives: evaluate antitumor activity of REGN4336 ± cemiplimab or nezastomig (ORR per modified PCWG3 criteria). Exploratory objectives include PSMA-PET imaging and tissue-based biomarker analysis. This is the first study to evaluate combined ×CD3 + ×CD28 bsAb in mCRPC. As of Sept 12, 2024, 35 pts have been enrolled, including 4 in Module 3. Clinical trial information: NCT05125016 .

Patient-reported outcome (PRO) assessment and reporting in first-line (1L) locally advanced or metastatic urothelial cancer (la/mUC) clinical trials: Results of a systematic literature review (SLR).

Journal of Clinical Oncology Mairead Kearney, Tom Macmillan, Julia Poritz et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.757

757 Background: Although maintaining health-related quality of life (HRQOL) is a primary goal of advanced cancer care, HRQOL and PROs usually are not measured or reported as robustly as efficacy outcomes in clinical trials. One example is la/mUC, an aggressive and incurable disease with a profound effect on patient HRQOL and functioning. With its changing therapeutic landscape in which newer agents with various efficacy and toxicity profiles are incorporated into clinical care, more attention must be given to the optimal deployment of PRO measures (PROMs). Our aim was to conduct a critical evaluation of currently used PROMs in la/mUC 1L trials. Methods: A SLR was conducted using 5 online databases to identify publications up to May 29, 2024 and recent conference abstracts of phase 2 or 3 clinical trials and real-world evidence (RWE) studies reporting PROs in the treatment of la/mUC. Results: Forty-nine studies were identified in the SLR (37 clinical trials; 12 RWE studies). Of the 37 clinical trials, 18 were in the 1L population. The most common PROMs in 1L trials were the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (n = 15) and the EuroQol-5D (n = 6). Other PROMs used were the Brief Pain Inventory–Short Form (n = 2), Functional Assessment of Cancer Therapy–Bladder (FACT-Bl; n = 1), National Comprehensive Cancer Network/FACT Bladder Symptom Index-18 (n = 1), and the Generic Quality of Life Inventory-74 (n = 1). PROMs were almost exclusively included as secondary endpoints (n = 16); only 2 trials included PROMs as exploratory endpoints. Prespecified analyses for HRQOL assessments were generally not stated in publications, and analytical methods and reporting varied. Of the 15 trials that used the EORTC QLQ-C30, 93% reported general health status/QOL, and 60% and 47% reported functional and symptom scales, respectively. Overall, HRQOL, functioning, and/or symptoms were maintained or improved, but meaningful changes in PRO scores reported were difficult to interpret due to the ways in which minimal clinically important difference thresholds were applied. Conclusions: Understanding the impact of various 1L treatment regimens on PROs relies on consistent assessment and transparent reporting. The findings of this SLR highlight the challenges in conducting cross-trial comparisons of PROs due to heterogeneity in study designs, patient characteristics, choice of PROMs, statistical analyses, and reporting of outcomes. To understand the symptom burden associated with novel therapeutics, it is recommended that the la/mUC research community develop a consensus regarding PRO development and implementation. This will facilitate interpretation of the patient experience, enhance clinical care, and guide informed treatment decision-making by clinicians and patients with la/mUC.

Outcomes with tandem or triplet autologous stem cell transplant for refractory germ cell tumors.

Journal of Clinical Oncology Michael Glover, Sumit Shah, Alice C. Fan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.632

632 Background: While Germ Cell Tumor (GCT) remain highly curable, up to 40% of patients (pts) with intermediate or poor risk advanced GCT will relapse. In the relapsed setting, high dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) may be pursued with curative intent. To predict the risk of post-AHCT relapse, the International Prognostic Factors Study Group created 5 risk categories incorporating 7 variables. The IPFSG score was created prior to the popularization of tandem/triplet transplants and validated in patients coming to AHCT in first relapse. Methods: We performed a retrospective analysis of all pts with GCT treated with AHCT at Stanford from 2017-2024. Pts were included if they were planned for doublet "tandem" (N Engl J Med 2007;357:340) or triplet (J Clin Oncol 2010;28:1706) AHCT with at least two months of follow up. Baseline characteristics, treatment history and outcomes were analyzed. For pts who came to transplant after >1 relapse, their IPFSG score was calculated based on most recent therapy prior to AHCT. Median relapse free survival (mRFS), overall survival (mOS), and 1-year outcomes were calculated from the final transplant and stratified by IPFSG score. A cox proportional analysis was performed to evaluate the multivariate for age, site of primary tumor, presence of brain metastases, and number of relapses prior to AHCT. Results: 57 pts were included in the analysis. Median age was 29 years (range 18-52). All pts were mobilized with G-CSF and underwent conditioning with carboplatin and etoposide. Three (5%) pts were planned for tandem and 54 (95%) for triplet AHCT. Most (97%) were non-seminomas or mixed germ cell tumors. 12 (21%) pts were transplanted after >1 relapse. The disease status at time of AHCT was partial remission tumor marker (PRM) negative in 9 (16 %), PRM positive in 43 (75%) and progressive disease in 5 (9%). 13 (23%) pts did not complete all scheduled transplants, all due to progression of disease. The median follow-up for the entire cohort was 330 days. The mRFS was 115 days, and mOS was 344 days. For the 49 pts at least one year from transplant, one-year RFS and OS are shown in the table. In a multivariate analysis, there was no association between death and age, site of primary tumor, presence of brain metastasis, disease status at transplant, or number of recurrences. Conclusions: Long term outcomes for patients with refractory GCT remain poor, though a subset of patients may still be cured with AHCT. The IPFSG accurately prognosticates outcomes in our real-world analysis. Outside of their contribution to IPFSG, variables such as disease status at transplant, site of metastasis, and number of recurrences did not have statistical significance. 1 year RFS and OS by IPFSG score. IPFSG Score Very low Low Intermediate High Very High Overall 1 yr RFS 100% (3/3) 66% (2/3) 78% (7/9) 20% (5/25) 11% (1/9) 37% (18/49) 1 yr OS 100 (3/3) 100% (3/3) 89% (8/9) 44% (11/25) 33% (3/9) 57% (28/49)

Simple Executive Function as an endophenotype of autism-ADHD, and differing associations between simple versus complex Executive Functions and autism/ADHD traits

Scientific Reports Alexandra Hendry, Rachael Bedford, Mary Agyapong et al. Feb 10, 2025 DOI: 10.1038/s41598-025-87863-2

Abstract Autism and ADHD are associated with difficulties with Executive Functions (EFs), but the prevalence and nature of these difficulties in early development is not well understood. In this longitudinal study, 107 children with a family history of autism and/or ADHD (FH-autism/ADHD), and 24 children with No-FH-autism/ADHD completed multiple EF tasks (5 at age 2 years, 7 at age 3 years). Parents reported on their child’s autism- (Q-CHAT at age 2, SRS-2 at age 3), and ADHD-related traits (CBCL DSM-ADHD scale, both ages). Compared to the No-FH-autism/ADHD group, the FH-autism/ADHD group showed lower scores on simple EFs (involving response inhibition, and holding in mind) at ages 2 and 3. Exploratory analysis linked FH-autism specifically with lower Executive Attention (top-down attentional control) at age 2, and the combination of FH-autism and FH-ADHD with lower Complex EF (involving selectively deploying responses, or updating information) at age 3. Three-year-olds’ Simple EF scores were negatively associated with ADHD-related traits. Complex EF scores were negatively associated with autism traits (before correcting for multiple comparisons). Toddlers with a family history of autism and/or ADHD may benefit from interventions to support simple EF development, whilst those already showing autistic traits may benefit from support with more-complex EF skills.

Primary tumor response to enfortumab vedotin with/without pembrolizumab in patients with upper tract urothelial cancer.

Journal of Clinical Oncology Evangelia Vlachou, Jeannie Hoffman-Censits, Nirmish Singla et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.684

684 Background: Cisplatin-based chemotherapy remains the standard for invasive urothelial cancer (UC) in the perioperative setting. Patients with upper tract UC (UTUC) are often ineligible for cisplatin due to disease- and surgery-related renal dysfunction. Modern perioperative trials focus on bladder UC, and cap or preclude enrollment for UTUC. Given the unprecedented activity of enfortumab vedotin and pembrolizumab (EV/P) in advanced UC and safety in impaired renal function, the assessment of this combination in earlier disease settings for patients with UTUC is an urgent need. This retrospective series evaluated the primary tumor response to EV and EV/P in aUTUC, a disease which is challenging to stage radiographically. Methods: This retrospective study included patients with intact primary UTUC tumors treated with EV and EV/P at Johns Hopkins. Baseline characteristics were collected through chart review. Primary tumor and overall response were assessed by 2 radiologists using RECIST1.1 criteria. Overall and primary tumor Response Rate (RR) [Complete Response (CR) + Partial Response (PR)] and Disease Control Rate (DCR) [CR + PR + Stable Disease (SD)] were calculated. Primary tumor was defined as any lesion in the ureter and/or renal pelvis. Non-measurable and sub-centimeter lesions (long axis <10mm) were deemed non-target per RECIST 1.1. Results: From December 2017 until June 2024, 50 patients with UTUC treated with EV or EV/P were identified. 22/50 patients had intact primary tumors and were included in this study. Median age was 72 years, 13 (59.1%) patients were male and 17 (77.3%) were white. Nineteen (86.4%) patients had pure urothelial histology and 18 (81.8%) had visceral metastases at baseline. Thirteen (59.1%) received EV and 9 (40.9%) EV/P. Three (13.6%) patients started EV at a reduced dose. Median number of EV cycles was 4 (range 0.5-14) and median duration of treatment was 3.3 months (range: 0.5-10). ORR was 36.4% and DCR was 72.3% in the entire cohort. Two (9%) patients had only non-target lesions at baseline and 6 (27.3%) had only non-target primary tumor lesions (Table). Conclusions: In this small study, EV and EV/P demonstrated promising radiographic response in primary UTUC lesions. Larger prospective studies are needed to assess the efficacy of this promising regimen in the perioperative setting for patients with this rare and aggressive disease. Radiologist-assessed RECIST response among patients with and without target lesions at baseline. Overall Response, N (%) Primary Lesion Response, N (%) Target lesions at baseline 20/22 16/22 Response Rate 8/20 (40.0) 4/16 (25.0) CR 0 (0) 0 (0) PR 8 (40.0) 4 (25.0) Disease Control Rate 17/20 (85.0) 14/16 (87.5) SD 9 (45.0) 10 (45.5) PD 3 (15.0) 2 (12.5) Only non-target lesions at baseline 2/22 6/22 Non-CR/Non-PD 2 (100) 6 (100) a a Non-target primary lesions decreased in size in 4/6 patients and remained stable in 2/6.

Examining community social vulnerability domains and influence on treatment selection for men with prostate cancer.

Journal of Clinical Oncology Jason Lloyd Goodloe, Samuel L Washington, Lufan Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.363

363 Background: For men with clinically localized PCa, treatment selection guided by patient age, comorbidities, and tumor characteristics can offer improved outcomes. While informative, these observations remain difficult to translate into local, state, and federal policy change to eliminate health disparities for communities at greater risk. We sought to examine how community SVI influences primary treatment, a key determinant of cancer outcomes, for men with clinically localized PCa treated primarily in a community setting. Methods: Men diagnosed and managed in CaPSURE practices after 1998 with clinically localized disease (no cM+ or cT4) and who underwent primary management within six months of diagnosis were identified. Community social vulnerability, as defined by census tract-level rankings from 0 to 1 with >90 th percentile deemed high, was appended to participants’ geocoded baseline addresses. SVI encompasses four domains (socioeconomic status, household characteristics, racial and ethnic minority status, and housing type and transportation). Prostate cancer treatment included prostatectomy, radiation, active surveillance/watchful waiting (AS/WW), primary androgen deprivation therapy (pADT). Multivariate multinomial logistic regression analyses examined associations between SVI and treatment selection, adjusted for patient, clinical, and tumor characteristics with sensitivity analyses using each SVI domain. Odds ratios and confidence intervals were reported with a two-sided p-value < 0.05 considered significant. Analysis was performed with SAS 9.4 for Windows. Results: 9,023 men diagnosed with low (43%) or intermediate (42%) risk disease and treated at community urology practices (90%) were included. Half (52%) underwent prostatectomy, 26% radiation, 13% ADT, and 9% AS/WW. Median SVI was 0.37 (IQR 0.17-0.59) and varied by theme: socioeconomic status (median 0.35, IQR 0.18-0.57), household characteristics (median 0.41, IQR 0.22-0.64), racial and ethnic minority status (median 0.37, IQR 0.17-0.63), and housing type and transportation (median 0.44, IQR 0.21-0.70). Correlations between SVI themes varied broadly (r = 0.21-0.63, p < 0.001). Having high SVI was associated with increased odds of non-invasive treatment compared to RP: RT (OR 1.56, 95% CI 1.39-1.77), AS/WW (OR 1.21, 95% CI 1.0-1.45), or pADT (OR 1.51, 95% CI 1.27-1.79). Individuals with high SVI by household characteristics had significantly greater likelihood of pADT (OR 1.61, 95% 1.34-1.94) compared to RP. Conclusions: Community social vulnerability independently increases the likelihood of non-surgical and potentially non-curative management of prostate cancer. SVI domains can provide specificity into which community characteristics may drive vulnerability and aid in identifying communities for targeted, policy-focused interventions.

Clinical features and prognostic value of CDK12 mutation in prostate cancer patients.

Journal of Clinical Oncology Hanyang Tao, Baijun Dong Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.103

103 Background: Studies have reported that biallelic loss of CDK12 in prostate cancer patients leads to genomic instability and an increase in tandem duplications. However, the prognostic relevance of CDK12 mutations has not been fully validated. Therefore, we assessed the clinical characteristics and outcomes of prostate cancer patients with CDK12 mutations, comparing this genomic subtype with prostate cancer lacking any genetic alterations. Methods: A total of 141 prostate cancer patients diagnosed between November 2010 and March 2024 were included. Genomic characteristics of biopsy tissues or plasma ctDNA were analyzed using next-generation sequencing to identify patients with CDK12 mutations and those without any genetic mutations. Due to the low incidence of biallelic CDK12 loss in this patient cohort, we integrated data from metastatic tumor biopsies and liquid biopsies. Notably, cfDNA and prostate cancer tumor biopsies from the same individuals have shown strong concordance in identifying somatic alterations. Results: We evaluated the clinical characteristics of the two groups of prostate cancer patients, and patients with CDK12 mutations were more aggressive and had a higher proportion of initial metastasis [77.05% (47/61) vs. 56.67% (51/80), P=0.013]. The median PSA at diagnosis was higher (60.63ng/ml vs. 38.02ng/ml), and the proportion of pathological Gleason score ≥8 was higher (85.25% (52/61) vs. 60.00% (48/80), P < 0.01). Patients with localized CDK12 mutations had shorter time to metastasis (median 34.10 months vs. 56.22 months, p < 0.001) and shorter survival than those without deleterious genetic alterations. Patients with CDK12 mutations had shorter median progression-free survival with conventional androgen-deprivation therapy, abiraterone, and docetaxel than those without deleterious mutations. However, the use of novel anti-male therapy, PARPi, immunotherapy or focal ablation can still prolong the survival of patients. Conclusions: CDK12 mutations are associated with metastasis and higher pathological malignancy, and they also serve as a predictive factor for poor clinical outcomes in patients receiving standard androgen deprivation therapy, abiraterone, or docetaxel treatment. Therefore, prostate cancer patients with CDK12 mutations may need to consider novel anti-androgen therapies, or combined interventions such as PARP inhibitors, immunotherapy, or focal treatments. This study underscores the importance of molecular diagnostics and the necessity of employing appropriate therapeutic strategies for CDK12-mutated prostate cancer. Overall, given the significant heterogeneity in clinical behavior, our research highlights the importance of this molecular subtype in prostate cancer and serves as a foundation for future prospective studies to further characterize the CDK12 subtype in prostate cancer.

Sea level trends along the South African coast from 1993 to 2022 using XTRACK altimetry, tide gauges, and GNSS measurements

Scientific Reports Franck Eitel Kemgang Ghomsi, Muharrem Hilmi Erkoç, Roshin P. Raj et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89258-9

Real world outcomes of <sup>177</sup> Lu-PSMA-617 PSMA in a racially diverse cohort of patients with metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Margo Gerke, Angelo Marra, Yuan Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.97

97 Background: 177 Lu-PSMA-617 is approved for treatment of mCRPC based on the VISION trial cohort with limited racial diversity. We analyzed real-world outcomes of 177 Lu-PSMA-617 in a diverse cohort. We aim to determine patient characteristics predictive of a clinical response to 177 Lu-PSMA-617. Methods: A retrospective analysis was conducted on patients with mCRPC treated with 177 Lu-PSMA-617 at Emory Winship Cancer Institute between 2022-2024. Primary endpoints were PFS, OS, and PSA reduction ≥ 50% (PSA50). Univariate association by survival analysis and logistic regression was carried out. Results: We analyzed 84 patients with PSMA PET+ mCRPC treated with 177 Lu-PSMA-617; 47.6% identified as Caucasian and 42.9% identified as Black. The median cohort age was 71.5 (IQR: 64-77.5). 35.6% had grade group 5 disease. Median number of prior lines of therapy was 5 (range: 4-7). 98.8% of patients had prior treatment with novel hormonal agents; 84.5% received prior taxane treatment. 84.5% were characterized as high-volume diseases using the CHAARTED trial criterion. Median baseline PSA was 105.5 (IQR: 20.4-454.8), and ALP was 103.5 (IQR: 72-177.5). The cohort completed a median number of 4 cycles of 177 Lu-PSMA-617; 35.7% completed six cycles. The overall cohort had a 12-month survival of 84.4%. 12-month survival rate was 88.3% in the white cohort compared to 81.4% in the non-white cohort. mPFS for the overall cohort was 6 months with a 12-month PFS rate of 41.9%. 12-month mPFS for the non-white cohort was 42.7% compared to 41.5% in the white cohort. 50.0% of the overall cohort had a PSA50 response. 56.1% of the non-white cohort had a PSA50 compared to 43.9% of the white cohort (p=0.377). Net BMI decline during treatment was associated with a 56% increased risk of mortality (OS HR 1.56, CI 1.18-2.06, p&lt;0.002). Conclusions: With similar PFS, OS, and PSA50 in this racially diverse cohort of patients with mCRPC, our results demonstrate 177 Lu-PSMA-617 effectiveness in a real-world patient population. Prospective studies are needed for further validation.

Hospitalizations in veterans treated with monotherapy vs combination therapy for metastatic hormone sensitive prostate cancer.

Journal of Clinical Oncology Kara Ingram, Robert Wilson, Jason M Doherty et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.72

72 Background: Current treatment of metastatic hormone sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT) monotherapy or combination therapy (ADT + docetaxel or an androgen receptor pathway inhibitor). However, no comparative studies have been conducted to assess the hospitalization rates and causes of admission between the two treatment groups. We assessed the hospitalization rates of the different therapies to determine adverse events and improve treatment selection in mHSPC. Methods: A nationwide retrospective study of 6,651 US Veterans with de novo mHSPC in the Veterans Health Administration between 2013-2021. Baseline characteristics for each treatment group were obtained including age, prostate serum antigen (PSA), total number of cardiac drugs, and total number of Anatomic Therapeutic Chemical (ATC) drugs. The five most frequent ICD codes associated with hospitalizations were obtained for each group, excluding the ICD codes for prostate cancer and bone metastases. Quasi-Poisson regression was used to determine differences in hospitalization rates between the two groups. Results: Evaluation of the median baseline characteristics between the two groups showed increased age and decreased PSA (Table). There was no difference between the number of cardiac drugs and total number of ATC drugs between the groups. The 5 most frequent ICD codes for monotherapy were AKI (17%), UTI (11%), essential hypertension (7%), sepsis (5%), and acute post-hemorrhagic anemia (4%). The 5 most frequent ICD codes for combination therapy were AKI (17%), UTI (13%), acute hypoxic respiratory failure (8%), sepsis (7%), and malnutrition (6%). The monotherapy group had a greater increase in hospitalization rates after therapy initiation when compared to combination therapy ( see table ). Quasi-Poisson regression for the hospitalization rates between the two groups had a p-value of 0.018. Conclusions: The rate of hospitalizations increased in the monotherapy treatment group compared to combination therapy. This is likely due to the monotherapy treatment group having a more advanced age and more severe comorbidities. Future directions could include comparing hospitalization rates of combination therapy with ARPI vs docetaxel. This analysis will guide physicians in selecting the more appropriate therapy according to a patient’s individual risk profile and co-morbidities. Age (p &lt; 0.001) PSA(p = 0.008) Pre-treatment hospitalization rate Post-treatment hospitalization rate ADT monotherapy(n = 5146) 75.0 76.2 120 per 1000 person-years 340 per 1000 person-years ADT combination therapy (n = 1505) 72.0 86.3 100 per 1000 person-years 260 per 1000 person-years